Disc teases potential NDA for rare skin disorder drug
In an end-of-Phase II meeting, the FDA indicated support for accelerated approval based on existing clinical data.
In an end-of-Phase II meeting, the FDA indicated support for accelerated approval based on existing clinical data.
What's Your Reaction?
